周三盘中,生物技术公司Vera Therapeutics, Inc.(VERA)股价大幅下跌6.20%,主要原因是公司公布的季度业绩不及预期。
根据公司发布的最新财报,截至6月30日的季度中,Vera Therapeutics调整后每股亏损1.20美元,远低于分析师预期的0.82美元亏损。公司当季净亏损高达7653万美元,而收入为零。这一结果显著低于华尔街预期,引发了投资者的担忧。
值得注意的是,Vera Therapeutics的股价表现持续疲软。数据显示,该公司股价本季度已下跌12.4%,今年迄今为止更是下跌了51.2%。尽管如此,分析师仍对该公司保持乐观态度。目前,华尔街对Vera Therapeutics的平均评级为"买入",12个月目标价中位数为67.50美元,较其最近收盘价20.64美元高出约69.4%。这种分歧可能会在未来一段时间内给该股票带来更多波动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.